Alnylam Pharmaceuticals' Operating Income rose 578.49% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.7 million, marking a year-over-year increase of 240.70%. This contributed to the annual value of -$176.9 million for FY2024, which is 37.31% up from last year.
As of Q3 2025, Alnylam Pharmaceuticals' Operating Income stood at $368.0 million, which was up 2,371.63% from -$16.2 million recorded in Q2 2025.
Alnylam Pharmaceuticals' Operating Income's 5-year high stood at $368.0 million during Q3 2025, with a 5-year trough of -$258.0 million in Q3 2022.
Over the past 3 years, Alnylam Pharmaceuticals' median Operating Income value was -$43.4 million (recorded in 2024), while the average stood at -$8.1 million.
Its Operating Income has fluctuated over the past 5 years, first plummeted by 135.96% in 2024, then surged by 578.49% in 2025.
Alnylam Pharmaceuticals' Operating Income (Quarterly) stood at -$194.6 million in 2021, then increased by 3.06% to -$188.6 million in 2022, then skyrocketed by 38.28% to -$116.4 million in 2023, then climbed by 9.66% to -$105.2 million in 2024, then skyrocketed by 578.49% to $368.0 million in 2025.
Its last three reported values are $368.0 million in Q3 2025, -$16.2 million for Q2 2025, and $18.1 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value